MUSCLE Flashcards
What differential diagnosis should be considered when a young, otherwise healthy person drops dead?
Hypertrophic cardiomyopathy.
[Cardiac myocytes don’t work as well as they ought to, so more filaments are added to each cell. # cells does not increase, only the size and number of filaments within each cell]
What is the muscle cell phenotype in hypertrophic cardiomyopathy?
1) hypertrophic cardiac myocytes
2) myocyte disarray
3) interstitial and replacement fibrosis (propensity to arrhythmia)
4) dysplastic intramyocardial arterioles (ischemia)
What type of mutation generally causes hypertrophic cardiomyopathy?
Missense mutation in structural genes.
What are the epidemiological outcomes for persons with HCM?
Most are fine. Some have angina, syncope, dyspnea. BUT, some will drop dead. <1%/year
Clinical Presentations HCM?
– Cardiac murmur (if LV outflow obstruction)
– Cardiac ‘Pump’ Failure (dyspnea, angina)
– Arrhythmia (syncope/sudden death)
– Sports/Family screening
Diagnosis?
Echocardiogram, EKG, MRI, Family history, genetic testing, chest‐X ray.
What is the inheritance?
Autosomal dominant.
How do muscles increase in size?
Length: recruit myoblasts (add nuclei)
Girth: recruit myoblasts and increase size and number of myofibrils (add sarcomeres)
What are the muscular cows lacking? Talk about that
Myostatin.
– Normally made and secreted by muscles as a negative feedback for muscle growth
– May be raised in AIDS patients with muscle wasting
Describe the steps in myostatin processing.
Mature myostatin produced after dimerization and cleavage. Inactive myostatin is bound to follistatin. Binding of dimerized myostatin (now unbound from follistatin) to Activin receptor IIB leads to Smad (tx factor) activation and changes in gene expression.
Malignant hyperthermia is what mode of inheritance? What causes the condition?
Genetic environmental disorder. Must be exposed to anasthetics.
Autosomal dominant. RYR1 mutation (70%).
Which anesthetic agents trigger malignant hyperthermia?
Halothane
Succinylcholine
What is the prevalence of malignant hyperthermia?
1/5000 - 1/100,000.
600 deaths/year in US
What is the presentation of malignant hyperthermia?
hypermetabolism, skeletal muscle damage, hyperthermia.
70% mortality if left untreated
Describe the cascade of events leading to malignant hyperthermia?
Stimulus (depolarization) travels down nerve, into muscle cell through t-tubule and through DHP receptors which trigger Ca channel opening (RyR). Ca channel does not close, causing a prolonged contraction. ATPase pumps Ca back into the SR continuously, generating massive amounts of heat.
Specific clinical signs of MH?
Masseter spasm on induction of anesthesia
Increased CO2 production
Hyperthermia
Rhabdomyolysis
[non specific: metabolic acidosis, tachycardia, tachypnea, hyperkalemia]